DEERFIELD, Ill.--(BUSINESS WIRE)--Sterigenics International LLC, the leading global provider of contract sterilization, gamma technologies and medical isotopes, and a portfolio company of Warburg Pincus and GTCR, today announced that it has acquired Sao Paulo based Companhia Brasileira de Esterilização (CBE), the largest specialist in sterilization and microbial load reduction in Latin America.
Founded in 1978, CBE was the first company to employ gamma sterilization methods in Brazil, and offers solutions through the largest particle accelerator (E-BEAM) in Latin America.
“This strategic geographic acquisition demonstrates our commitment to expanding our global footprint in order to meet our customers’ growing needs,” said Michael Mulhern, CEO of Sterigenics International. “Going forward, we will continue investing in the future of Sterigenics and building upon our leadership position.”
“We are very excited to add such a high-quality company as CBE to Sterigenics,” said Philip Macnabb, President of Sterigenics International LLC. “CBE brings three facilities into our network with a total processing capacity of 12 million cubic feet. With the addition of CBE we now offer six locations for processing in Latin America, including sites in Costa Rica and Mexico.”
In 2014, a Sterigenics affiliate acquired Nordion, the world’s largest provider of Cobalt-60, an isotope that produces gamma radiation and is a critical component of the gamma sterilization process, creating the only vertically integrated sterilization services company in the world. Additional acquisitions in 2014 included Florida-based gamma irradiation operator FTSI, as well as Gammarad, Italy’s leading gamma irradiation sterilization company, which now serves as the company’s second gamma sterilization facility in Western Europe.
About Sterigenics International LLC
Sterigenics International LLC, along with its affiliates, is a global leader in outsourced contract sterilization services, gamma technologies and medical isotopes, and the only vertically integrated sterilization company in the world. Operating out of 47 facilities in 13 countries across the Americas, Europe and Asia, Sterigenics provides contract sterilization and ionization services for the medical device, pharmaceutical, food safety, and high-performance materials industries. Through its SteriPro® Labs service, Sterigenics offers microbiological and analytical testing and consultancy to assist customers in developing and maintaining sterilization solutions in medical devices, tissue/implantable products, and pharmaceuticals and biologics fields. Affiliate Nordion positions Sterigenics as the world’s largest provider of Cobalt-60 used in the gamma sterilization process as well as medical isotopes used in the diagnosis and treatment of various diseases and cancers. Sterigenics International LLC and its affiliates serve more than 2,500 customers around the world and is owned by private equity firms Warburg Pincus and GTCR.
About Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm focused on growth investing. The firm has more than $35 billion in assets under management. The firm’s active portfolio of more than 120 companies is highly diversified by stage, sector and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value.
Founded in 1966, Warburg Pincus has raised 14 private equity funds, which have invested more than $50 billion in over 720 companies in more than 35 countries. The firm is headquartered in New York with offices in Amsterdam, Beijing, Frankfurt, Hong Kong, London, Luxembourg, Mauritius, Mumbai, San Francisco, São Paulo and Shanghai. For more information, please visit www.warburgpincus.com.
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.